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SINTESIS SERBUK β-TCP   
MELALUI KAEDAH PEMENDAKAN BASAH DAN HIDROTERMA. 
 
ABSTRAK 
 
Matlamat kajian ini adalah untuk mensintesis β-TCP  [β-Ca3(PO4)2] menggunakan 
Ca(OH)2 dan H3PO4 sebagai bahan mula. Dua pendekatan telah digunakan dalam 
kajian ini untuk menghasilkan β-TCP, iaitu kaedah pemendakan basah dan kaedah 
hidtroterma. Kajian ini telah mengesahkan bahawa kesan kelajuan pengadukan 
memainkan peranan yang lebih penting berbanding tempoh pengadukan. Keadaan 
optimum untuk menghasilkan serbuk β-TCP fasa tunggal adalah : (1) kelajuan 
pengadukan : 200rpm ; (2) tempoh pengadukan: 2 jam ; (3) suhu kalsin : 900oC 
dengan tempoh rendam 1 jam. Lebih penting, kajian ini telah membuktikan bahawa 
fasa dalam serbuk sebelum kalsin untuk mendapatkan β-TCP fasa tunggal adalah 
campuran fasa monetit [CaHPO4] dan hidrosiapatit [Ca10(PO4)6(OH)2].  
Berdasarkan kajian pemendakan, kaedah hidroterma telah digunakan untuk 
mensintesis β-TCP menggunakan Ca(OH)2 dan H3PO4 sebagai bahan mula. Analisis 
XRD menunjukkan serbuk yang dihasilkan mempunyai fasa campuran brushite 
[CaHPO4.2H2O] dan HA berbanding dengan fasa campuran monetit dan HA dari 
kaedah pemendakan. Serbuk kemudian dikalsin pada suhu 900oC selama 1 jam. XRD 
mengesahkan bahawa serbuk β-TCP fasa tunggal telah berjaya dihasilkan. 
Namun, ketumpatan β-TCP yang diperolehi daripada kaedah pemendakan 
adalah 3.1g/cm3, (hampir sama dengan nilai β-TCP komersil (ρ=3.17g/cm3)) manakala 
kaedah hidroterma menghasilkan serbuk yang mempunyai  ketumpatan lebih tinggi 
(iaitu sekitar 3.7 g/cm3). Ini dipercayai berpunca daripada pemampatan (sebelum 
kalsin) dan seterusnya pensinteran (selepas kalsin) serbuk kepada butir-butir bersaiz 
seragam sewaktu sintesis. Tambahan pula, serbuk β-TCP yang disintesis 
menggunakan kedua-dua kaedah didapati telah menepati keperluan Piawaian implan 
pembedahan ASTM F1088-04a dengan kandungan toksik yang sangat rendah. 
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SYNTHESIS OF β-TCP POWDER  
VIA WET PRECIPITATION AND HYDROTHERMAL METHODS. 
 
ABSTRACT 
 
The purpose of this study is to synthesize β-TCP [β-Ca3(PO4)2] using Ca(OH)2 
and H3PO4 as the starting material. Two approaches were used in this work to produce 
β-TCP, namely a precipitation method and a hydrothermal method. This research work 
reveals that the effect of stirring speed plays significant role than that of stirring 
duration. The optimum conditions to produced a single-phase β-TCP are: (1) stirring 
speed of 200 rpm; (2) stirring duration of 2 hours; (3) calcination temperature of 900oC 
for 1 hour soaking time. Since β-TCP cannot be directly precipitated from aqueous 
solution, it was found  that the most optimum precursor phase(s) in the as-prepared 
powder to produce β-TCP after calcination is a mixture phase of monetite [CaHPO4] 
and hydroxyapatite [Ca10(PO4)6(OH)2].  
Based on the precipitation study, a hydrothermal method was used to 
synthesize β-TCP using Ca(OH)2 and H3PO4 as the starting materials in a high-
pressure reactor. XRD study shows that the as-prepared powder is a mixture phase of 
brushite [CaHPO4.2H2O] and HA instead of monetite and HA as found in the 
precipitation method. The powder was then calcined at 900oC for 1 hour and it was 
found that a single-phase β-TCP was also successfully produced.  
The density of β-TCP obtained by the precipitation method is around 3.1g/cm3 
(almost similar to a commercial β-TCP (ρ=3.17g/cm3)) whilst the hydrothermal method 
produced powders of higher density (density around 3.7 g/cm3). This is attributed to the 
packing and sintering of the powder into uniformly-sized grains during synthesis. In 
addition, the β-TCP powders synthesized using both methods satisfy the requirements 
of the Standard for surgical implant, via ASTM F1088-04a with a very low level of toxic 
elements. 
1 
CHAPTER 1 
 
INTRODUCTION 
 
1.1 Introduction 
 
 Biomaterials are the emerging fields that are growing rapidly to fulfill the 
demand in medicine and dentistry.  Over the past few decades, new 
biomaterials for bone replacement, total hip prosthesis and dental implants have 
been synthesized and commercialized for various needs. Currently, thousands 
of these materials can be found easily in the market. The market for orthopedic 
biomaterials over the world is worth over US$25 billion in 2006 and with a 
growth rate of more than 5% a year (refer Table 1.1). The market for orthopedic 
biomaterials is expected to increase each year due to the need for better 
solution for injuries, diseases and ageing population all over the world. 
 
Table 1. 1: Prediction of market share of orthopedic biomaterials over the 
world in five years from 2007 to 2011 (Driscoll, 2006). 
Year Worldwide sales (US$ Billions) Growth (%) 
2006 25.764  
2007 27.122 5.3 
2008 28.562 5.3 
2009 30.989 8.5 
2010 31.708 2.5 
2011 33.425 5.4 
Average growth rate (%)  5.4 
  
 However, none of orthopedic biomaterials provides a perfect solution for 
guiding bone healing, because there always remain the questions about 
mechanical stability, long term in-vivo biocompatibility and biodegradability, the 
2 
study on orthopedic biomaterials increases every year (Tadic and Beckmann, 
2004). 
 
1.2 Problem statement  
The orthopedic biomaterials market consists primarily of bone graft 
substitutes, bone growth factors, degradable tissue fixation and tissue 
technologies for cartilage regeneration. Generally, orthopedic prostheses 
should offer a functional life of at least 20 years to match the life span of most 
patients. This presents a considerable problem for most orthopedic biomaterial 
(Batchelor and Chandrasekaran, 2004).  
In Malaysia, orthopedic biomaterial researches especially on bone graft 
and degradable materials are still in the infancy stage. Up to now, Malaysia has 
spent more than RM20 million each year to buy synthetic bone graft from 
foreign countries such as Switzerland, Germany and the United States. 
Therefore, the Malaysian government intends to produce bone graft of it own 
with the supporting research from Universiti Sains Malaysia (USM), Malaysian 
Institute for Nuclear Technology Research (MINT), Universiti Kebangsaan 
Malaysia (UKM) and International Islamic University Malaysia (IIUM). (Material 
Medical Malaysian website, 2006). 
 Due to the high demands for bone substitutes, many researches have 
been conducted to produce synthetic bone substitutes in large quantities as 
reported by Jinawath et al., (2002), Saeri et al.,(2003), Kondo et al., (2005), 
Murugan et al., (2006) and Horch et al., (2006). Synthetic bone graft materials 
such as ceramics, polymers and metals were introduced as an alternative to the 
traditional bone substitute. Among these materials, calcium phosphate ceramics 
3 
such as hydroxyapatite (HA) and β-Tricalcium phosphate (β-TCP) are the most 
suitable materials with excellent biological properties. There are not so many 
researches up to date that have been done on the synthesis of β-TCP. Most of 
the researches focused on synthesis of HA powders or biphasic HA/β-TCP 
powder such as Zhang et al., (2001), Anee et al., (2003), Liu et al., (2003), 
Murugan and Ramakrishna (2003) and Cheng et al., (2006). However, the 
interest on β-TCP increases in recent years due to the high competition in 
producing bone graft in the market share of orthopedic biomaterial. Generally β-
TCP was prepared by a solid-state reaction and a wet chemical reaction. The 
solid state reaction was reported by Lee et al., (2007), Choi and Kumta (2007), 
and Yoshida et al., (2007) whilst the wet chemical reaction was carried out by 
Koc (2004), Vallet-Regi et al., (2004), Zou et al., (2005) and Kwon et al., (2006) 
(all of these methods will be discussed later in chapter 2). These synthesized β-
TCP powders were not stable in term of thermal properties whereby they were 
converted to α-TCP at temperature above 1125oC.   
 The present research modified the study of Cheang and Khor (1995), 
Saeri et al., (2003), Afshar et al., (2003) and Nagai and Nishimura, (1980) to 
synthesize β-TCP. According to Saeri et al., (2003) and Afshar et al., (2003), 
HA can be synthesized by using the system of Ca(OH)2 and H3PO4 with a Ca/P 
ratio of 1.67. This reaction was expected to be developed towards an industrial-
scale method to produce HA with the correct stoichiometric composition, 
according to the Equation (1.1): 
 
10Ca(OH)2 + 6H3PO4 Æ Ca10(PO4)6(OH)2 + 18H2O                 (1.1) 
 
4 
 The advantages of this reaction are: 
• The reaction involves no foreign elements 
• The only by-product of the reaction is water 
 
In the present research work, a wet chemical reaction such as the 
precipitation method and also the hydrothermal method were carried out to 
prepare β-TCP. Instead of using a Ca/P ratio of 1.67, a modification was 
attempted whereby Ca(OH)2 and H3PO4 were use as starting materials with a 
Ca/P ratio of 1.5. The mechanism of phase transformation in both of these 
synthesis methods were fully explored.  
 
1.3 Objectives of research 
This study is focused on certain variables such as reaction parameters 
(stirring speed and stirring duration), calcinations variables (calcination 
temperature and calcination soaking duration). Therefore, the objectives of this 
research are: 
1. To synthesize single-phase β-TCP powders by a wet 
precipitation method and a hydrothermal method. 
2. To investigate the optimum reaction parameters (stirring speed, 
stirring duration) and calcination condition (calcination 
temperature, soaking time) to form a single phase β-TCP. 
3. To study the mechanism of phase transformation of the 
synthesized powder upon calcination. 
4. To characterize the physical properties of single phase β-TCP 
powder such as density and morphology. 
5 
 
1.4 Research scope 
 In general, the research is divided into two parts which will be described 
in more detail in chapter 3.  The first part is the synthesis of β-TCP using a wet 
precipitation method from Ca(OH)2 and H3PO4 starting materials with a Ca/P 
ratio of 1.5 The effect of reaction parameters (stirring speed, stirring duration) 
and calcination conditions (calcination temperature, soaking time) were studied. 
The characterization of the product powders were carried out using XRD, FTIR, 
SEM and the density of powders were observed. 
 The second part is the synthesis of β-TCP using a hydrothermal method 
from the same Ca(OH)2 and H3PO4 staring material with a Ca/P ratio of 1.5. In 
this part, the effect of stirring speed and calcination condition were studied. The 
results of first part and second part were compared to understand the effect of 
each method. The full detail of each method will be described in chapter 3, 
however the methodology adopted in this research work can be summarized in 
the flow charts shown in Figure 1.1 and 1.2 
6 
 
Figure 1. 1: Flow chart of the wet precipitation method (the first part). 
H3PO4 solution Ca(OH)2 solution 
Precipitation reaction 
Filtering and washing 
Powder characterization 
Drying  
As-prepared powder 
Calcination 
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Figure 1. 2: Flow chart of the hydrothermal method (the second part). 
H3PO4 solution Ca(OH)2 solution 
Hydrothermal reaction 
Filtering and washing 
Powder characterization 
Drying  
As-prepared powder 
Calcination 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Biomaterials 
 
 The term biomaterials can be interpreted in two ways;  first, as biological 
materials such as tissue and blood; and second, as implant materials that 
replace the function of the biological material (Park and Lake, 1992). According 
to its legal definition as frequently referenced in the literature, a biomaterial is a 
nonviable material used in a medical device, intended to interact with a 
biological system (Williams, 1988). Thus, a biomaterial must always be 
considered in its final fabricated and sterilized form. It was Williams, in 1988, 
who coined the words “biomaterial” and “biocompatibility” to indicate the 
biological performance of these materials. Thus, materials that are 
biocompatible can also be considered as biomaterials. 
In 1982, the National Institute of Health Consensus Development 
Conference organized in America defined a biomaterial as “any substance 
(other than drug) or combination of substances, synthetic or natural in origin, 
which can be used for any period of time, as a whole or as a part of a system 
which treats, augments, or replace any tissue, organ, or function of the body” 
(The National Institute of Health Consensus Development Program: Clinical 
Applications of Biomaterials website, 1982). 
 Biomaterials can broadly be classified as biological biomaterials and 
synthetic biomaterials. Biological materials can be further classified into soft and 
hard tissue types whilst synthetic materials can be further grouped into metallic, 
polymeric, ceramic and composite biomaterials. Table 2.1 shows the various 
classifications and some examples of biomaterials. 
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Table 2. 1: Classification of biomaterials (Hin, 2004) 
I. Biological materials II. Synthetic biomedical materials 
1. Soft tissue:  
• Skin, tendon, pericardium, 
cornea,  etc. 
1. Polymeric:  
• Ultra High Molecular Weight 
Polyethylene (UHMWPE), 
Polymethylmethacrylate (PMMA), 
Polyethyletherketone (PEEK), 
Silicone, Polyurethane (PU), 
Polytetrafluoroethylene (PTFE) 
2. Hard Tissue:  
• Bone, dentine, cuticle, etc 
2. Metallic:  
• Stainless steel, Cobalt-based alloy 
(Co-Cr-Mo), Titanium alloy (Ti-Al-
V), Gold, Platinum 
3. Ceramic: 
• Alumina (Al2O3), Zirconia (ZrO2), 
Carbon, Hydroxyapatite 
[Ca10(PO4)6(OH)2], Tricalcium 
phosphate [Ca3(PO4)2], Bioglass 
[Na2O(CaO)(P2O3)(SiO2)], Calcium 
aluminate [Ca(Al2O4)] 
4. Composite:  
• Carbon Fiber (CF) composite such 
as: CF/PEEK, CF/UHMWPE, 
CF/PMMA 
 
Synthetic materials are currently being used for biomedical applications.  
Since they have different structures, they have varying properties and uses in 
the body. These types of synthetic biomaterials will be presented in the next 
section.  
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2.2 Types of Synthetic Biomaterials 
2.2.1 Metallic biomaterials 
Metals have been used almost exclusively for load-bearing implants, 
such as hip and knee prostheses, fracture fixation wires, pins, screws, and 
plates (Dee et al., 2002). Metals have also been used as parts of the artificial 
heart valves, e.g.  such as vascular stents and pacemaker leads. Although pure 
metals are sometimes used, alloys (metal containing two or more elements) 
frequently provide improvement in material properties, such as strength and 
corrosion resistance. Three alloy systems dominate biomedical metals: 316L 
stainless steel, cobalt-chromium-molybdenum alloy, and pure titanium and 
titanium alloy. The main consideration in selecting metals and alloys for 
biomedical application are biocompatibility, appropriate mechanical properties, 
corrosion resistance and reasonable cost. 
 The mechanical properties of materials are of great importance when 
designing load-bearing orthopedic and dental implants. The mechanical 
properties of a biomaterial can best be described by its modulus of elasticity, 
tensile strength, elongation to failure and fracture toughness. Some mechanical 
properties of metallic biomaterials are listed in Table 2.2.  With a few 
exceptions, the high ultimate tensile and fatigue strength of metals, compared to 
ceramic and polymers make them the materials of Choi and Kumtace for 
implants that carry mechanical loads. 
The elastic moduli of the metals listed in Table 2.2 are at least seven 
times greater than that of natural bone. This mismatch of mechanical properties 
can cause “stress shielding”, a condition characterized by bone resorption (loss 
of bone) in the vicinity of implants. This clinical complication arises because the 
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preferential distribution of mechanical loading through the metallic prosthesis 
deprives bone. 
  
Table 2. 2: Selected properties of metallic biomaterials (Dee et al., 2002) 
Materials Young’s 
modulus, E 
[GPa] 
Yield 
strength,  
σy [MPa] 
Tensile 
strength, 
σUTS [MPa] 
Fatigue limit,
 σend [MPa] 
Stainless steel 190 221-1,213 586-1,351 241-820 
Co-Cr alloys 210-253 448-1,606 655-1,896 207-950 
Titanium 110 485 760 300 
Ti-6Al-4V 116 896-1,034 965-1,103 620 
Natural bone 15-30 30-70 70-150 - 
  
2.2.2 Ceramic and glass biomaterials 
 Ceramics, in general, can be defined as the art and science of making 
and using solid articles composed of inorganic and nonmetallic materials for 
functional applications. Typically, ceramics are fabricated by synthesizing 
powders, followed by shaping and consolidation processes, which enable the 
fabrication of objects of different shapes and sizes. Ceramics are refractory, 
inorganic compounds made of metals and nonmetals such as O, N, C, S. 
Exceptions to this general category include diamond, graphite, carbon 
nanotubes, and pyrolized carbons (Kingery et al., 1976). 
 In recent years, ceramics and composites can also be used to augment 
or replace various parts of the body, particularly the bone. Ceramics that can  
be used for the body are called bioceramics. Their relative inertness to body 
fluids, high compressive strength, and pleasing aesthetic appearance have led 
to the use of ceramics in dentistry as dental crown. Some carbons have been 
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used as implant for blood interfacing application such as heart valves. Due to 
their high specific strength as fibers and owing to their biocompatibility, 
ceramics are also used as reinforcing components of composite implant 
materials and for tensile loading applications such as tendons and ligaments. 
 Unlike metals and polymers, ceramics do not shear plastically due to the 
ionic nature of the bonding and a minimum number of slips systems. Thus 
ceramics are non ductile and are responsible for almost zero creep at room 
temperature. Ceramics are susceptible to notches and cracks (micro-cracks) 
since they do not undergo plastic deformation. Ceramics fracture elastically on 
initiation of cracks. At the crack tip, stress could be many times larger than the 
stress in the material away from the tip, leading to stress concentration 
weakening in the material (Billotte, 2000). 
 In general, ceramics are hard: diamond is the hardest, with a hardness 
index of 10 on the Moh’s scale followed by alumina (Al2O3, hardness 9) and 
quartz (SiO2, hardness 8). Other characteristics are: high melting temperatures 
and low conductivity of electricity and heat. 
 The desired properties of bioceramics are: 
• Non toxic 
• Non-carcinogenic 
• Non-inflammatory 
• Biocompatible 
• Biofunctional for its lifetime in the host 
 
Ceramics used in fabricating implants can be classified as biodegradable 
or resorbable (non-inert); bioactive or surface reactive (semi-inert) and 
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nondegradable (relatively inert). Al2O3, ZrO2, Si3N4 and carbons are inert 
bioceramics. Certain glass-ceramics and dense hydroxyapatite (HA) are semi-
inert (bioreactive) and calcium phosphates are degradable ceramics. Some Ca-
phosphates also contain alumina (AlCaP) which can be biodegradable. 
Ceramics and glasses are also used as components of hip implants, 
dental implants, middle ear implants and heart valves. Overall, however, these 
biomaterials have been used less extensively than either metals or polymers. 
Some ceramics that have been used for biomedical application are listed in 
Table 2.3. 
 
Table 2. 3: Ceramics used in biomedical application (Dee et al., 2002). 
Ceramics Chemical formula Remarks 
Alumina Al2O3 Bio-inert 
Zirconia ZrO2 Bio-inert 
Pyrolytic carbon  Bio-inert 
Bioglass Na2O.CaO.P2O3-SiO2 Bioactive 
Hydroxyapatite  
(sintered at high temperature) 
Ca10(PO4)6(OH)2 Bioactive 
Hydroxyapatite  
(sintered at low temperature) 
Ca10(PO4)6(OH)2 Biodegradable 
Tricalcium phosphate Ca3(PO4)2 Biodegradable 
  
The fundamental principle in classifying ceramic biomaterials is based on 
chemical reactivity with the physiological environment (Figure 2.1).  Relative 
inert bioceramic, such as structural Al2O3, tend to exhibit inherently low levels of 
reactivity which peak on the order of 104 day (over 250 years). Bioactive 
ceramic, such as bioglass have a substantially higher level of reactivity peaking 
on the order of 100 days. Resorbable or degradable bioceramics, such as 
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tricalcium phosphate, have even higher levels of reactivity peaking on the order 
of 10 days. This broad spectrum of chemical behavior has led to a 
corresponding range of engineering design materials (Hench, 1991). 
 
 
Figure 2.1: Bioactivity spectrum for various bioceramic implants. (Hench, 1991). 
 
The major drawbacks to the use of ceramics and glasses as implants are 
their brittleness and poor tensile strength properties (see Table 2.4). Although 
they can have outstanding strength when loaded in compression, ceramics and 
glasses fail at low stresses when loaded in tension or bending. Among 
biomedical ceramics, alumina has the highest mechanical properties, but its 
tensile properties are still below those of metallic biomaterials. Additional 
advantageous properties of alumina are its low coefficient of friction and wear 
rate. As a consequence of these properties, alumina has been used as a 
bearing surface in joint replacements. 
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Table 2. 4: Mechanical properties of ceramic biomaterial (Dee et al., 2002). 
Materials Young’s 
modulus , E 
[GPa] 
Compressive 
strength, σUCS 
[MPa] 
Tensile 
strength, σUTS 
[MPa] 
Alumina 380 4500 350 
Bioglass-ceramic 22 500 56-83 
Calcium 
phosphate 
40-117 510-896 69-193 
Pyrolytic carbon 18-28 517 280-560 
 
The mechanical properties of calcium phosphates and bioactive glasses 
make them unsuitable as load-bearing implants. Clinically, hydroxyapatite has 
been used as a filler for bone defects and as implant in load-free anatomic sites 
(for example, nasal septal bone and middle ear). In addition, hydroxyapatite has 
been used as a coating on metallic orthopedic and dental implants to promote 
their fixation in bone. In these cases, the underlying metal carries the load, 
whereas the surrounding bone strongly bonds to hydroxyapatite. 
 
2.2.3 Polymeric biomaterials 
 Polymers are the most widely used materials in biomedical applications. 
They are the materials of Choi and Kumtace for cardiovascular devices as well 
as for replacement and augmentation of various soft tissues. Polymers are also 
used in drug delivery system, in diagnostic aids, and as a scaffolding material 
for tissue engineering applications.  Example of current applications include 
vascular graft, heart valves, artificial hearts, breast implants, contact lenses, 
intraocular lenses, components of extracorporeal oxygenators, dialyzers and 
plasmapheresis units, coating for pharmaceutical tablets and capsules, sutures, 
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adhesives and blood substitutes. Examples of polymers and their uses are 
given in Table 2.5. 
 
Table 2. 5: Examples of biomedical application of polymers (Dee et al., 2002). 
Applications Polymers 
Cardiovascular 
implants 
Polyethylene; polyvinylchloride (PVC); polyester; silicone 
rubber; polyethylene terephthalate; 
polytetraflouroethylene 
Orthopedic implant Ultra high molecular weight polyethylene (UHMWPE); 
polymethyl methacrylate (PMMA) 
Drug release Polylactide-co-glycolide 
Tissue engineering Polylactic acid; polyglycolic acid; poly lactide-co-glycolide 
  
The mechanical properties of polymers depend on several factors, 
including the composition and structure of the macromolecular chains and their 
molecular weights. Table 2.6 lists some mechanical properties of selected 
polymeric biomaterials. Compared with metals and ceramics, polymers have 
much lower strengths and moduli but they can be deformed to a greater extent 
before failure. Consequently, polymers are generally not used in biomedical 
applications that bear loads (such as body weight). Ultra high molecular weight 
polyethylene (UHMWPE) is an exception, as it is used as a bearing surface in 
hip and knee replacements. The mechanical properties of polymers, however, 
are sufficient for numerous biomedical application (some of which are listed in 
Table 2.5). 
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Table 2. 6: Mechanical properties of biomedical polymers (Dee et al., 2002). 
Polymer 
Tensile strength, 
σUTS [MPa] 
Young’s 
Modulus, E 
[GPa] 
Elongation
% 
Polymethyl methacrylate (PMMA) 30 2.2 1.4 
Nylon 6/6 76 2.8 90 
Polyethylene terephthalate 53 2.14 300 
Polylactic acid 28-50 1.2-3 2-6 
Polypropylene 28-36 1.1-1.55 400-900 
Polytetrafluoroethylene 17-28 0.5 120-350 
Silicone rubber 2.8 Up to 10 160 
Ultra high molecular weight 
polyethylene (UHMWPE) 
≥ 35 4-12 ≥ 300 
 
2.3 Calcium phosphate ceramics (CPC) 
2.3.1 General properties of calcium phosphate ceramics: 
As mentioned in the section 2.2.2, β-TCP can be classified to the calcium 
phosphate group. Thus, calcium phosphate will be focused in this section.  
There are several forms of calcium phosphate. They typically form a family of 
compounds called “apatites”. The name “apatite” was derived from “apataw”, 
the Greek word to deceive, since it was confused with several other similar 
looking minerals until chemical analysis conducted proved that calcium 
phosphate composition is similar to enamel, dentin and bone (see Table 2.7). 
There are several types of calcium phosphate, such as tricalcium 
phosphate (TCP), hydroxyapatite (HA), dicalciumphosphate dihydrate (DCPD or 
brushite), dicalcium phosphate anhydrous (DCPA or monetite).  They exist in 
different forms and phases depending on temperature, partial pressure of 
waters and the presence of impurities (Hench, 1998). Different phases are used 
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in different applications depending upon whether a degradable or a bioactive 
material is desired (Billotte, 2000). Table 2.8 summarized various phases of 
calcium phosphate currently used in the biomedical industry. Table 2.9 presents 
solubility of different phases of calcium phosphate in aqueous solution. 
 
Table 2. 7: Comparison between enamel, dentin, bone and synthetic apatite 
(Lacout, 1992). 
Element % Enamel Dentine Bone Synthetic apatite 
Calcium 
Phosphorous 
Carbon dioxide 
Magnesium 
Sodium 
Potassium 
Chlorine 
Fluorine 
Sulphur 
Zinc 
Silicon 
36.1 
17.3 
3.0 
0.5 
0.2 
0.3 
0.3 
0.016 
0.1 
0.016 
0.003 
35.0 
17.1 
4.0 
1.2 
0.2 
0.07 
0.03 
0.017 
0.2 
0.018 
- 
35.5 
17.1 
4.4 
0.9 
1.1 
0.1 
0.1 
0.015 
0.6 
- 
0.04 
39.0 
18.5 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Ca/P atomic ratio 1.62 1.59 1.61 1.667 
Crystallinity good poor poor good 
 
The mechanical properties of synthetic calcium phosphates vary 
considerably (Table 2.10). The wide range in the properties of polycrystalline 
calcium phosphates are due to the variations in their structure and 
manufacturing processes. Depending on the final firing condition, calcium 
phosphate can be hydroxyapatite or β-TCP. In many instances, both types of 
structures exist in the final product (Park and Lakes, 1992). 
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Table 2. 8: Various phases of calcium phosphate ceramics (Guelcher and 
Hollinger and Hollinger, 2006). 
Phases 
Chemical 
formulae 
Mineral 
name 
Ca/P 
ratio 
Hydroxyapatite (HA) Ca10(PO4)6(OH)2 Apatite 1.67 
α-Tricalcium phosphate (α-TCP) Ca3(PO4)2 Whitlockite 1.5 
β-Tricalcium phosphate (β-TCP) Ca3(PO4)2 Whitlockite 1.5 
Dicalcium phosphate dihydrate 
(DCPD) 
CaHPO4.2H2O Brushite 1.0 
Dicalcium phosphate anhydrous 
(DCPA) 
CaHPO4 Monetite 1.0 
 
Table 2. 9: Solubility of different calcium phosphates (Schdmidt, 1993).  
Phases 
Solubility 
In water [g/l] In 0.1 Ml HCl 
HA Insoluble Soluble 
β-TCP 0.02 Soluble 
Brushite 0.3 Soluble 
Monetite 0.2 Soluble 
  
Table 2. 10: Physical properties of calcium phosphates (Park and Lakes, 1992) 
Property Value 
Elastic modulus (GPa) 
Compressive strength (MPa) 
Bending strength (MPa) 
Hardness (Vickers) 
Poisson’s ratio 
Density (theoretical, g/cm3) 
4.0 – 117 
294 
147 
3.43 
0.27 
3.16 – 3.2 
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In addition, calcium phosphates are widely used in food and 
pharmaceutical products, for instance as a calcium source in mineral tablets, 
baking powders, cheese and meat products or as abrasive agents in 
toothpaste. They are also used as tablets fillers/binders because of their good 
binding properties, excellent flowability, low costs, chemical purity and relatively 
few incompatibilities with pharmaceutical drugs. Table 2.11 shows the 
commercially available calcium suitable for direct tablet. All these substances 
are also available as fine powders for wet granulation, and food industry.  
 
Table 2. 11: Calcium phosphates used for direct tablet (Schmidt and Herzog 
and Herzog, 1993) 
Formula Trade names Manufacturer 
CaHPO4.2H2O 
(Brushite) 
Bekapress D2. 
Dentphos L5. 
Di-Cafos. 
 
Di-Tab. 
Emcompress Dihydrate. 
BK Ladenburd, Ladenburg, FRG.
BK Landenburg. 
Chemische Fabrik Budenheim, 
Budenheim, FRG. 
Rhone-Poulenc, New York, USA.
E. Mendell Co., New York, USA. 
CaHPO4 
(Monetite) 
A-Tab. 
Di-Cafos A. 
Di-Cafos AN. 
Emcompress Anhydrous. 
Rhone-Poulenc. 
Chemische Fabrik Budenheim. 
Chemische Fabrik Budenheim. 
E. Mendell Co. 
Ca10(PO4)6(OH)2 Tri-Cafos S. 
Tri-Tab. 
Chemische Fabrik Budenheim. 
Rhone-Poulenc. 
 
Among these calcium phosphate ceramics, bioresorbable or 
biodegradable ceramics are most interesting. The concept of degradable 
ceramics as bone substitutes was introduced in 1969 by Hentrich. However, 
long before this plaster of paris was already being used as a bone substitute.  
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(Peltier, 1957). Degradable ceramics, as the name implies, degrade upon 
implantation in the host and are slowly replaced by advancing tissue (such as 
bone) (Guelcher and Hollinger and Hollinger, 2006). The rate of degradation 
varies from material to material. Most bioresorbable ceramics except for 
biocoral and plaster of paris are essentially variations of calcium phosphate. 
Example of biodegradable bioceramics include: aluminum – calcium – 
phosphorus oxides (AlCaP) (Mattie and Bajpai, 1988), glass fiber and their 
composites (Alexander et al., 1987), coral [(Guillemin et al., 1989) and (Khavari 
and Bajpai, 1993)]. Typical uses of biodegradable ceramics are drug delivery 
devices (Abrams and Bajpai, 1994) and for repair of damaged bone due to 
disease or trauma (Scheidler and Bajpai, 1992). A drawback of calcium 
phosphate ceramics is their complicated fabrication process and particularly 
difficult shaping. Nevertheless, calcium phosphate ceramics have gained and 
will keep a place in clinical practice, as an alternative for autologous bone 
grafting and as base material for implantable teeth. 
 
2.3.2 Hydroxyapatie 
The ideal Ca/P ratio of hydroxyapatite is 1.67 and the calculated density 
is 3.219g/cm3. Substitution of OH- ion with fluoride gives the apatite greater 
chemical stability due to the closer coordination of fluoride (symmetric shape),  
as compared to the hydroxyl (asymmetric, two atoms) by the nearest calcium. 
This is why fluoridation of drinking water helps in resisting caries of the teeth. 
(Park and Lakes, 1992). 
Hard tissue such as bone, dentin, and dental enamel are natural 
composites which contain hydroxyapatite (or a similar mineral), as well as 
22 
protein, other organic materials and water. Enamel is the stiffest hard tissue, 
with an elastic modulus of 74 GPa, and containing the most mineral 
hydroxyapatite. Dentin (E  = 21 GPa) and compact bone (E = 12 to 18 GPa) 
contain comparatively less mineral. The Poisson’s ratio for the mineral or 
synthetic hydroxyapatite is about 0.27, which is close to that of bone (~ 0.3) 
(Park and Lakes, 1992). 
 
2.3.3 Tricalcium phosphate (TCP)  
β-TCP is the low-temperature phase in the CaO - P2O5 phase diagram. 
β-TCP transforms to α-TCP at 1125oC and above this, up to 1430oC, α-TCP is a 
stable phase. Above 1430oC, the super α-TCP form becomes stable until the 
melting point of 1756oC The ideal Ca/P ratio of β-TCP is 1.5 and the theoretical 
density is 3.17 g/cm3 as reported by Guelcher and Hollinger and Hollinger 
(2006). Research has shown that tricalcium phosphate degrades faster than 
calcium phosphate, [Ca2P2O7], which also degrades faster than hydroxyapatite 
(Bhat, 2006). 
According to Kalita et al., (2007) and Guelcher and Hollinger (2006), β-
TCP does not form in aqueous system under normal laboratory conditions 
except with the introduction of small amounts of Mg2+ ions. Kalita et al., (2007) 
and Billotte (2003) also agree that crystallization of various salts of calcium 
phosphate like hydroxyapatite and β-TCP depends on Ca/P ratio, presence of 
water, impurities and temperature. For instance, in a wet environment and at a 
lower temperature (<900oC), the formation of hydroxyapatite is most likely to 
happen, but in a dry atmosphere and at a high temperature, β-TCP is more 
likely to form. Both forms are very tissue compatible and are used as bone 
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substitutes in a granular form or a solid block. A multi-crystalline porous form of 
β-TCP has been used successfully to correct periodontal defects and augment 
bone contours (Metsger et al., 1982). X-ray diffraction of β-TCP powder shows 
an average interconnected porosity of over 100μm (Lemons and Niemann, 
1979). 
Since TCP is a degradable temporary bone space filler material, when 
implanted, TCP will interact with body fluids to form hydroxyapatite as follow: 
(Grook, 1984). 
 
4Ca3(PO4)2 + 2H2O Æ Ca10(PO4)6(OH)2 + 2Ca2+ + 2HPO42-             (2.1) 
 
This reaction will decrease the pH of the local solution and further 
increase the solubility of TCP. Theoretically, degradable β-TCP is an ideal 
implant material. After implantation, TCP will degrade with time and be replaced 
with natural tissues. It leads to the regeneration of tissue instead of their 
replacement and thus solves the problem of interfacial stability. However, in 
clinical applications, some limitations restrict the use of degradable TCP: 
Firstly, the mechanical performance of an implant must match the repair 
rate of body tissues. According to Legeros et al., (1995), Ducheyne et al., 
(1990), the order of relative solubility of α-TCP, β-TCP and HA had been 
suggested as α-TCP ~ β-TCP and very much greater than HA. In order to use 
for surgical implantation, the degradation rate of the implant must be controlled 
very well. To solve this problem, a composite between bioactive (semi-solubility) 
and bioresorbable (high solubility) was mixed together to control the 
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degradation rate, for instance the biphasic calcium phosphate (BCP) between 
hydroxyapatite and β-TCP. 
Secondly, large quantities of the implant materials must be handled by 
the body cells and as such the constituents of a degradable implant must be 
metabolically acceptable. TCP implants dissolve by grain-boundary 
degradation. The released grains may cause a potential metabolic problem 
because of their size (Gross et al., 1988). 
 
2.3.4 Trace element measurement of HA and β-TCP for surgical implant 
The concentration of trace elements in HA and β-TCP shall be limited for 
surgical implant purpose (see Table 2.12). In this research work, β-TCP 
powders synthesized satisfy the requirement of the ASTM F1088-04a standard. 
The concentrations of trace elements in β-TCP powders will be discussed in 
Chapter 4. 
 
Table 2. 12: Standard specification of HA and β-TCP for surgical implant 
(Furcola, 2005). 
Standard specification of HA and β-TCP for surgical implant 
Element Maximum concentration, [ppm] HA β-TCP 
As 3 3 
Cd 5 5 
Hg 5 5 
Pb 30 30 
Standard ASTM F1185-03 ASTM  F1088-04a 
 
 
 
2.3.5 Thermal behaviour of calcium phosphate ceramic 
 Schmidt and Herzog (1993) studied the thermal behavior of calcium 
phosphate. Four types of calcium phosphate were used for his study: (1) 
